The Stop TB partnership and Otsuka Pharmaceutical have arranged for the inclusion of delamanid in the Global Drug Facility (GDF). This inclusion will allow the drug to be available at a cost of US$1,700 per six-month treatment. Delamanid has been tested in children as young as six, may be able to be administered in pregnant women (based on physician discretion), and pending the results of a phase III clinical trial, recommendations for its use may be broadened. Unfortunately, the drug has yet to reach many patients outside of clinical trials, as the drug is currently only registered in areas where there are relatively few MDR-TB patients. To read the full press release, visit the Treatment Action Group website here. To read more, visit the Médecins Sans Frontières website here, or view a press release from Treatment Action Group here and Otsuka here.